stockrow
Saturday 7 November 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
- EPS
- −10.3%
- Free cash flow
- −46.7%
- Total debt
- −94.0%
Quarter to June 2026, against a year earlier
20.62
1.20
+6.18%
Follow TECX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(32.21%) | (37.82%) | (31.42%) | (33.80%) | |
| (30.20%) | (35.83%) | (29.74%) | (32.23%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.37%) | (29.79%) | (36.62%) | (38.71%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.34) | (3.29) | (3.49) | (3.82) | |
Free Cash Flow |
(62.58) | (60.22) | (65.54) | (72.38) | |
Capital Expenditures |
(0.14) | (0.14) | (0.13) | (0.24) | |
| Other line items | |||||
Cash ROIC |
(11.66%) | (11.91%) | (14.02%) | (16.05%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,033.91) | (1,333.90) | (1,824.29) | (2,373.12) | |
Operating CF/Net income |
0.93 | 0.81 | 0.78 | 0.84 | |
Depreciation/Fixed assets |
1.10 | 1.16 | 1.29 | 1.47 | |
Capex/Depreciation |
(0.09) | (0.10) | (0.10) | (0.19) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.34) | (3.28) | (3.48) | (3.80) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates